RVTY logo

RVTY

Revvity, Inc.NYSEHealthcare
$88.94+1.16%OpenMarket Cap: $9.94B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

41.15

PEG

P/B

1.39

P/S

3.48

EV/EBITDA

16.38

DCF Value

$115.24

FCF Yield

5.1%

Div Yield

0.3%

Margins & Returns

Gross Margin

50.2%

Operating Margin

13.0%

Net Margin

8.5%

ROE

3.2%

ROA

7.5%

ROIC

2.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$772.1M$98.4M$0.87
FY 2025$2.86B$241.7M$2.08
Q3 2025$698.9M$46.7M$0.40
Q2 2025$720.3M$55.2M$0.47

Analyst Ratings

View All
JP MorganNeutral
2026-03-31
JP MorganNeutral
2026-02-03
JefferiesHold
2026-02-03
Wells FargoEqual Weight
2026-02-03
TD CowenBuy
2026-02-03

Trading Activity

Insider Trades

View All
Gonzales Anitaofficer: Please See Remarks
SellWed Mar 18
Gonzales Anitaofficer: Please See Remarks
SellWed Mar 18
Gonzales Anitaofficer: Please See Remarks
SellTue Mar 10
Gonzales Anitaofficer: Please See Remarks
SellTue Mar 10
Victor Miriameofficer: Please See Remarks
SellThu Feb 26

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NYSE

Beta

1.13

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Peers